Pharmaceutical composition comprising amphetamines complexed with ion-exchange resin particles
The invention relates to a pharmaceutical composition comprising amphetamines complexed with ion-exchanged resin particles to form drug-resin particles. The composition provides for prolonged therapy.
1. A pharmaceutical composition comprising amphetamines complexed with ion-exchange resin particles to form drug-resin particles, wherein 30 to 50% by weight of said amphetamines are present in a first plurality of immediate release drug-resin particles and 50 to 70% by weight of said amphetamines are present in a second plurality of drug-resin particles that are coated with a delayed release coating.
2. The composition of claim 1 , wherein the second plurality of drug resin particles comprises a triggered-release coating triggered by a pH change.
3. The composition of claim 2 , wherein the triggered-release coating is cellulose acetate phthalate, cellulose acetate trimellitate, hydroxypropyl methylcellulose phthalate, polyvinyl acetate phthalate, carboxymethylethylcellulose, co-polymerized methacrylic acid/methacrylic acid methyl esters, co-polymerized methacrylic acid/ acrylic acid ethyl esters, or mixtures thereof.
4. The composition of claim 1 , wherein the resin particles are strong acidic cation exchange resins, selected from the group consisting of polistirex, polacrilex, cholestyramine, polacrilin or mixtures thereof.
5. The composition of claim 1 , wherein 40%-50% by weight of said amphetamines are present in the first plurality of drug-resin particles and 50%-60% by weight of said amphetamines are present in the second plurality of drug-resin particles.
6. The composition of claim 5 , wherein about 45% by weight of said amphetamines are present in the first plurality of drug-resin particles and about 55% by weight of said amphetamines are present in the second plurality of drug-resin particles.
7. The composition of claim 1 , wherein the composition is a liquid suspension, chewable composition, or an orally disintegrating tablet composition.
8. The composition of claim 1 , wherein said amphetamines in said drug-resin particles comprise 25% levo-amphetamine and 75% dextro-amphetamine.
9. The composition of claim 1 , wherein the amount of said amphetamines is 2-60 mg.
10. The composition of claim 1 , wherein 40-45% of said amphetamines are released within the first 45 minutes after the drug-resin particles are introduced into an in vitro dissolution assay, followed by a period of substantially no amphetamine release from 45 minutes to 2 hours, and concluding with period of from 2 to 8 hours during which substantially all of the remaining amphetamines are released, wherein the conditions of the dissolution assay are an initial dissolution medium of 0.1 N HCL, and after 2 hours, the medium is adjusted to a pH of about 6.8; and the dissolution assay is performed using a USP Apparatus 2.
11. The composition of claim 1 , wherein the delayed release coating releases substantially all of the amphetamines in the second plurality of drug-resin particles within about 60 minutes after initiation of the delayed release.
12. A pharmaceutical composition comprising amphetamines complexed with ion-exchange resin particles to form drug resin particles, wherein said composition comprises a first plurality of immediate release drug-resin particles and a second plurality of drug-resin particles that are coated with a delayed release coating, wherein a mammal receiving said composition, in the presence of ethanol, is exposed to a reduced amount of amphetamines compared to when said mammal receives a composition without resin particles particles in the presence of ethanol, said composition comprising a mixture of dextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine aspartate, and amphetamine sulfate.
13. The composition of claim 1 , wherein the amount of said amphetamines is equivalent to the total amount of amphetamines present in a 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, or 30 mg reference composition without resin particles which comprises a mixture of dextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine aspartate, and amphetamine sulfate.
14. A pharmaceutical composition comprising a mixture of dextro- and levo-amphetamines complexed with ion-exchange resin particles to form drug resin particles, wherein said composition comprises a first plurality of immediate release drug-resin particles and a second plurality of drug-resin particles that are coated with a delayed release coating, wherein said composition is an orally disintegrating tablet and is effective to provide a mean plasma concentration profile in human ADHD patients which has the following AUC and C max values for a 30 mg total dose, or respective AUC and C max values directly proportional thereto for a total dose other than 30 mg:
(a) an AUC 0-4 of 85.8 ng hr/mL −20% /+25% and a C max of 44.5 ng/mL −20% /+25% for dextroamphetamine and/or an AUC 0-4 of 26.3 ng hr/mL −20% /+25% and a C max of 14.2 ng/mL −20% /+25% for levoamphetamine;
(b) an AUC 0-5 of 126.3 ng hr/mL −20% /+25% and a C max of 44.5 ng/mL −20% /+25% for dextroamphetamine and/or an AUC 0-5 of 39.1 ng hr/mL −20% /+25% and a C max of 14.2 ng/mL−20% /+25% for levoamphetamine;
(c) an AUC 4-12 of 291 ng hr/mL −20% /+25% and a C max of 44.5 ng/mL −20% /+25% for dextroamphetamine and/or an AUC 4-12 of 95.1 ng hr/mL −20% /+25% and a C max of 14 . 2 ng/mL −20% /+25% for levoamphetamine;
(d) an AUC 5-12 of 250.5 ng hr/mL −20% /+25% and a C max of 44.5 ng/mL −20% /+25% for dextroamphetamine and/or an AUC 5-12 of 82.3 ng hr/mL −20% /+25% and a C max of 14.2 ng/mL −20% /+25% for levoamphetamine; and/or
(e) an AUC 0-24 of 613.3 ng hr/mL −20% /+25% and a C max of 44.5 ng/mL −20% /+25% for dextroamphetamine and/or an AUC 0-24 of 204.9 ng hr/mL −20% /+25% and a C max of 14.2 ng/mL −20% /+25% for levoamphetamine.
15. A pharmaceutical composition comprising a mixture of dextro- and levo-amphetamines complexed with ion-exchange resin particles to form drug resin particles, wherein said composition comprises a first plurality of immediate release drug-resin particles and a second plurality of drug-resin particles that are coated with a delayed release coating, wherein said composition is a liquid suspension and is effective to provide a mean plasma concentration profile in human ADHD patients which has the following AUC and C max values for a 30 mg total dose, or respective AUC and C max values directly proportional thereto for a total dose other than 30 mg:
(a) an AUC 0-4 of 104.7 ng hr/mL −20% /+25% and a C max of 46.3 ng/mL −20% /+25% for dextroamphetamine and/or an AUC 0-4 of 31.8 ng hr/mL −20% /+25% and a C max of 14.6 ng/mL −20% /+25% for levoamphetamine;
(b) an AUC 0-5 of 148.6 ng hr/mL −20% /+25% and a C max of 46.3 ng/mL −20% /+25% for dextroamphetamine and/or an AUC 0-5 of 45.7 ng hr/mL −20% /+25% and a C max of 14.6 ng/mL −20% /+25% for levoamphetamine; and/or
(c) an AUC 4-12 , of 300.3 ng hr/mL −20% /+25% and a C max of 46.3 ng/mL −20% /+25% for dextroamphetamine and/or an AUC 4-12 , of 96.8 ng hr/mL −20% /+25% and a C max of 14.6 ng/mL −20% /+25% for levoamphetamine.
16. A pharmaceutical composition comprising amphetamines complexed with ion-exchange resin particles to form drug resin particles, wherein said composition comprises a first plurality of immediate release drug-resin particles and a second plurality of drug-resin particles that are coated with a delayed release coating, wherein said composition, when containing about a total amphetamine dose of 30 mg, will produce in a human, a mean plasma concentration versus time curve (ng/ml versus hours) having an area under the curve (AUC 0-∞ ) of about 1140 to about 1240 for total amphetamines.
17. A pharmaceutical composition comprising dextro-amphetamines, levo-amphetamines, or a racemic mixture thereof complexed with ion-exchange resin particles to form drug resin particles, wherein said composition comprises a first plurality of immediate release drug-resin particles and a second plurality of drug-resin particles that are coated with a delayed release coating, wherein one or more in vivo pharmacokinetic parameters of the composition selected from the group consisting of C max , AUC 0-5 , AUC 5-12 , AUC 5-24 , AUC 5-t , AUC 0-12 , AUC 0-24 , AUC 0-t ,and AUC 0-∞ have a 90% confidence interval with upper and lower bounds within a range from 90%-115% of the value of the same parameter(s) for a bioequivalent reference composition.
18. A pharmaceutical composition comprising amphetamines complexed with ion-exchange resin particles to form drug resin particles, wherein said composition comprises a first plurality of immediate release drug-resin particles and a second plurality of drug-resin particles that are coated with a delayed release coating, wherein said composition is a liquid suspension and a human receiving said composition substantially contemporaneously with food is exposed to an increased amount of amphetamines in the first 4 hours compared to a human receiving a reference composition comprising a mixture of dextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine aspartate, and amphetamine sulfate.
19. A pharmaceutical composition comprising amphetamines complexed with ion-exchange resin particles to form drug resin particles, wherein about 50% by weight of said amphetamines are present in a first plurality of immediate release drug-resin particles and about 50% by weight of said amphetamines are present in a second plurality of drug-resin particles that are coated with a delayed release coating.
20. A pharmaceutical composition comprising amphetamines complexed with ion-exchange resin particles to form drug resin particles, wherein said composition comprises a first plurality of immediate release drug-resin particles and a second plurality of drug-resin particles that are coated with a delayed release coating and wherein said composition has an in vivo fasted serum profile with a first and second peak wherein said first peak occurs between 1 and 3 hours after ingestion of the composition and said second peak occurs between 4 and 7 hours after ingestion and is the C max .
21. The composition of claim 1 , wherein said amphetamines comprise a mixture of dextro-and levo-amphetamines.